Additionally, in an in vitro engineered model of human skeletal muscle tissue, tofacitinib, a Janus kinase (JAK) inhibitor approved for RA treatment, effectively counteracted the adverse impacts of IFNγ on the strength, size, and architecture of skeletal muscle [50,51]. This evidence concerns the gene IFNG and rheumatoid arthritis.